Melissa E. Murray, United States of America

Mayo Clinic Florida Neuroscience Research
Melissa E. Murray, Ph.D., is a translational neuropathologist in the Department of Neuroscience at Mayo Clinic in Florida. Dr. Murray holds the academic rank of Associate Professor of Neuroscience and has received numerous awards for her research that focuses on investigating the heterogeneity of Alzheimer’s disease (AD). She uses a multi-disciplinary approach to uncover neurobiologic differences underlying atypical and typical neuropathologic subtypes of AD and their relevance to clinical presentations observed antemortem. She received an R01 from the National Institute of Aging and an Alzheimer’s Association Research Grant to continue to pursue her research on atypical AD. Dr. Murray has published more than 180 scientific papers with the bulk of her studies centered on identifying the clinicopathologic characteristics and neuroimaging biomarkers of AD and related dementias. Her state of Florida funded initiatives seek to improve our understanding of ethnoracial differences in neuropathologic distribution and severity of AD and co-existing pathology. She is a co-PI of the multi-site Neuropathology Core for the Longitudinal Early Onset Alzheimer’s Disease Study (LEADS) and serves as immediate past Chair for the International Society to Advance Alzheimer's Research and Treatment’s Atypical Alzheimer's disease Professional Interest Area group.

Moderator of 2 Sessions

FORUM ON APPLICATIONS OF NEUROPSYCHOLOGY, PET, MRI, EEG, PLASMA AND CSF FOR DIAGNOSIS AND ASSESSMENT OF TREATMENT EFFECTS

Date
10.03.2021, Wednesday
Session Time
19:30 - 20:30
Session Icon
Live
LIVE SYMPOSIUM DISCUSSION

LIVE DISCUSSION - BIOMARKERS, IMAGING IN AD, PD AND LBD

Date
12.03.2021, Friday
Session Time
17:30 - 18:00
Session Icon
Live

Presenter of 4 Presentations

SELECTIVE VULNERABILITY OF THE CHOLINERGIC HUB IN THE CONTEXT OF AGING AND ALZHEIMER DISEASE SUBTYPES

Session Type
SYMPOSIUM
Date
10.03.2021, Wednesday
Session Time
10:00 - 12:00
Room
On Demand Symposia B
Lecture Time
10:45 - 11:00
Session Icon
On-Demand

Abstract

Abstract Body

Objectives: The nucleus basalis of Meynert (nbM), a major cholinergic hub, is selectively vulnerable to neurofibrillary tangle pathology in Alzheimer’s disease (AD, Hanna Al-Shaikh 2020). Our goal is to examine demographic modifiers of this vulnerability to examine the contribution of age, sex, and occupation.
Methods: The FLorida Autopsied Multi-Ethnic (FLAME) cohort was examined for neurofibrillary tangle accumulation utilizing thioflavin-S microscopy to identify mature and extracellular tangles in the anterior nbM. Age at onset of cognitive problems and highest level of occupation (scaled to 0-6) was retrospectively examined. AD cases lacking known mutations were examined and age 65 was used to stratify young onset AD (YOAD) and late onset AD (LOAD).
Results: YOAD cases had nearly twice the number of tangles (median=16) compared to LOAD (median=9, p<0.001). YOAD also had fewer neurons (median=21/mm2) than LOAD (median=27/mm2, p<0.001). Regression analysis of greater tangle accumulation in the nbM revealed younger age (p<0.001), higher Braak stage (p<0.001), and presence of Lewy body disease (p<0.001) as significant predictors, but not sex, occupation, or presence of APOE-ε4. Regression analysis of higher neuronal density in the nbM revealed older age (p<0.001), lower Braak stage (p<0.001), lack of Lewy body disease (p<0.001), and higher occupation level (p=0.020) as significant predictors, but not sex or presence of APOE-ε4.
Conclusions: In addition to age, severity of disease course and co-occurrence of Lewy body disease should be considered when investigating selective vulnerability of the nbM. Interestingly, occupation may modify neuronal volume of the nbM, but not necessarily spare accumulation of pathology.
Hide